Jaguar Health Inc (NASDAQ:JAGX)’s share price reached a new 52-week low during trading on Thursday . The stock traded as low as $0.36 and last traded at $0.35, with a volume of 44347 shares changing hands. The stock had previously closed at $0.43.

Separately, ValuEngine upgraded Jaguar Health from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st.

The company has a quick ratio of 0.31, a current ratio of 0.46 and a debt-to-equity ratio of 1.03.

In related news, major shareholder Nantucket Investments Ltd sold 325,615 shares of the company’s stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $1.83, for a total value of $595,875.45. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 4.70% of the stock is currently owned by corporate insiders.

A hedge fund recently bought a new stake in Jaguar Health stock. Acadian Asset Management LLC bought a new position in shares of Jaguar Health Inc (NASDAQ:JAGX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 99,557 shares of the biotechnology company’s stock, valued at approximately $141,000. Acadian Asset Management LLC owned approximately 1.14% of Jaguar Health at the end of the most recent reporting period. Institutional investors own 5.07% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Jaguar Health (JAGX) Sets New 52-Week Low at $0.36” was published by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.watchlistnews.com/jaguar-health-jagx-sets-new-52-week-low-at-0-36/2671096.html.

About Jaguar Health (NASDAQ:JAGX)

Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

Further Reading: NASDAQ

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.